Western pharmaceutical companies are urging the Trump administration to allow them to continue forming partnerships with Chinese firms for promising drug candidates, despite a 2025 law restricting U.S. investment in Chinese technology. According to reports, an industry trade group has been actively lobbying the Treasury Department to ensure that the upcoming implementation of the Comprehensive Outbound Investment National Security Act (COINS) does not restrict collaborative deals in the pharmaceutical sector. The COINS Act mandates federal screening of deals involving sensitive technologies with certain countries, but the Treasury has so far shown reluctance to fully incorporate pharmaceuticals into the regulatory framework.
Meanwhile, the U.S. Food and Drug Administration has released documents ahead of an advisory committee meeting that suggest a favorable outlook for Grail’s multi-cancer early detection blood test. The test is currently available as a laboratory-developed diagnostic, but formal FDA approval is expected to facilitate reimbursement from Medicare and other major insurance payers. Although investor sentiment remains positive, the agency’s documentation notes certain anomalies that could influence the final regulatory outcome.
Also Read
- Pet Bird Bite Causes Rare LASIK Flap Displacement and Perforation 14 Years After Surgery
- As Health Insurance Costs Soar, Healthcare Workers Also Feel the Pinch
- Ruptured Aorta’s ‘Tree Bark’ Texture Unveils Untreated Syphilis After Severe Crash
- A Parkinson’s Drug Prescribed for a 9-Year-Old’s Foot Problems Unexpectedly Eased Her Years of Severe Headbanging
